Emergent BioSolutions Reports Financial Results for First Quarter 2011
ROCKVILLE, Md., May 05, 2011 (BUSINESS WIRE) — Emergent BioSolutionsInc. (NYSE: EBS) announced its financial results for the first quarter ended March 31, 2011.
For 1Q 2011, total revenues were $18.5 million as compared to $46.8 million in 2010. In addition, for 1Q 2011 the company recorded a net loss of $21.4 million, or $0.61 per [...]
In: BioDefense, Biothrax, Business, Chief Executive Officer, Chief financial officer, Revenue · Tagged with: BARDA, Biothrax, Emergent BioSolutions, Fuad El-Hibri, Research and development, Revenue
Emergent BioSolutions Awarded HHS Contract Valued at up to $186.6 Million to Develop rPA Anthrax Vaccine
ROCKVILLE, MD, September 17, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract, valued at up to $186.6 million, with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), for the development of a recombinant protective antigen [...]
In: Biothrax, Chief Executive Officer, Emergent Bioslutions, Food and Drug Administration, Fuad El-Hibri, Research and development, U.S. Food and Drug Administration, United States · Tagged with: Anthrax vaccines, Clinical trial, Emergent BioSolutions, Food and Drug Administration, Research and development, U.S. government
Emergent BioSolutions Awarded NIAID Contract That Increases Potential Funding to Over $58 Million for Advanced Development of Third Generation Anthrax Vaccine
New Contract Valued at up to $28.7 Million for Phase II Clinical Trial
ROCKVILLE, Md., Sep 01, 2010 –Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $28.7 million with the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of [...]
In: Biothrax, Chief Executive Officer, Emergent Bioslutions, Food and Drug Administration, Fuad El-Hibri, Research and development, U.S. Food and Drug Administration · Tagged with: Anthrax vaccines, Biothrax, Emergent BioSolutions, Food and Drug Administration, National Institutes of Health, Research and development
Emergent BioSolutions Recognized as Biotechnology Firm of the Year by Tech Council of Maryland
ROCKVILLE, MD, May 13, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has been named Biotechnology Firm of the Year at the Tech Council of Maryland’s (TCM) Annual Tech Awards. This award acknowledges the company that best exemplifies the spirit of Maryland’s biotechnology community as well as its presence and leadership within the [...]
In: Chief Executive Officer, Food and Drug Administration, Fuad El-Hibri, Research and development, Tech Council of Maryland · Tagged with: Business, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Research and development, Tech Council of Maryland
Emergent Biosolutions Appoints Dr. W. James Jackson As Chief Scientific Officer
Emergent BioSolutions Inc. (NYSE: EBS) announced today that W. James Jackson, Ph.D., has been appointed chief scientific officer, effective immediately. Dr. Jackson will report directly to Fuad El-Hibri, chairman and chief executive officer.
As CSO, Dr. Jackson will lead the company’s scientific evaluation of new products and technology platforms and will be responsible for building and [...]
In: Uncategorized · Tagged with: Biotechnology and Pharmaceuticals, Business, Chief executive officer, Infectious disease, Pharmaceutical, Research and development, University of Georgia, US Food and Drug Administration
Emergent Biosolutions And Ninebio Sdn. Bhd. Announce Joint Venture In Malaysia
Newly formed company to focus on creating critical R&D and manufacturing infrastructure and supplying biodefense countermeasures within Asia and other territories.
Emergent BioSolutions (NYSE: EBS) and Ninebio Sdn. Bhd. (“9Bio”) today announced the formation of a joint venture in Malaysia that will focus on creating critical biologics infrastructure and supplying biodefense countermeasures, including BioThrax® (Anthrax Vaccine [...]
In: Uncategorized · Tagged with: Chief executive officer, Emergent BioSolutions, MALAYSIA, Private Securities Litigation Reform Act, Research and development, SEC, United States, US Food and Drug Administration